+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

THU0427Sustained Improvements in Skin Outcomes Following Certolizumab Pegol Treatment of Psoriatic Arthritis Patients with Prior Anti-TNF Exposure or Severe Skin Involvement at Baseline



THU0427Sustained Improvements in Skin Outcomes Following Certolizumab Pegol Treatment of Psoriatic Arthritis Patients with Prior Anti-TNF Exposure or Severe Skin Involvement at Baseline



Annals of the Rheumatic Diseases 74(Suppl 2): 353.2-354




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064769893

Download citation: RISBibTeXText

DOI: 10.1136/annrheumdis-2015-eular.1840


Related references

SAT0298 Effect of Certolizumab Pegol on Signs and Symptoms in Patients with Psoriatic Arthritis from the Rapid-PSA Study: Impact of Baseline Skin Involvement and Prior Anti-TNF Therapy. Annals of the Rheumatic Diseases 72(Suppl 3): A684-A685, 2013

FRI0472Improvements in Joint Outcomes of Psoriatic Arthritis over 4 Years of Treatment with Certolizumab Pegol in Patients with and without Prior Anti-TNF Exposure. Annals of the Rheumatic Diseases 75(Suppl 2): 609-609, 2016

OP0077Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Psoriatic Arthritis with and without Prior Anti-Tumor Necrosis Factor Exposure: 96-Week Outcomes from the Rapid-Psa Trial. Annals of the Rheumatic Diseases 73(Suppl 2): 90.1-90, 2014

Sat0564Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol. Annals of the Rheumatic Diseases 74(Suppl 2): 864.2-865, 2015

Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol. Value in Health 18(7): A654, 2015

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. Rmd Open 1(1): E000119, 2015

SAT0260Effect of Certolizumab Pegol on the Multiple Facets of Psoriatic Arthritis as Reported by Patients with and without Prior Anti-Tnf Exposure: 24-Week Patient-Reported Outcome Results of Rapid-PSA Study. Annals of the Rheumatic Diseases 72(Suppl 3): A670.1-A670, 2013

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure. Reumatologia Clinica 2018:, 2018

210.Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Exposure. Rheumatology 53(Suppl_1): i137-i138, 2014

Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study. Value in Health 18(7): A707-A708, 2015

Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Psoriatic Arthritis. Value in Health 17(7): A387-A388, 2014

Sat0405Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol. Annals of the Rheumatic Diseases 73(Suppl 2): 741.1-741, 2014

AB0372Effect of Certolizumab Pegol on Workplace and Household Productivity in US Patients with Rheumatoid Arthritis with or without Prior Anti-Tumor Necrosis Factor Exposure: Results from the PREDICT Study. Annals of the Rheumatic Diseases 73(Suppl 2): 927.4-928, 2014

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Annals of the Rheumatic Diseases 74(1): 44-51, 2015

SAT0281Impact of Imputation Methodology on Radiographic Progression Outcomes in the Rapid-Psa Study Of Certolizumab Pegol In Patients With Psoriatic Arthritis. Annals of the Rheumatic Diseases 72(Suppl 3): A678.2-A678, 2013